Department of Urology, Keio University School of Medicine, Tokyo, Japan
* Correspondence to: Dr M. Oya, Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Tel: +81-3-5363-3825; Fax: +81-3-3225-1985; Email: moto-oya{at}sc.itc.keio.ac.jp
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Materials and methods:: The expression of phosphorylated Akt (p-Akt), total Akt and PTEN was analyzed by Western blotting in 45 renal cell carcinoma (RCC) patients. The Bad and phosphorylated Bad (p-Bad) statuses were analyzed in 20 RCC patients. A phosphatidylinositol ether analog was used as an Akt inhibitor to treat four RCC cell lines, namely Caki-1, KU19-20, SW839 and Caki-2.
Results:: The PTEN expression in RCC was observed to decrease and p-Akt expression to increase significantly in comparison with that in the corresponding normal kidney tissue. The PTEN expression inversely correlated with the p-Akt expression. These alterations were specific for clear cell type RCC, but not for papillary or chromophobe type RCC. Alterations in Bad phosphorylation were also specifically observed in clear cell type. The Akt inhibitor induced apoptosis in KU19-20 and Caki-2 cells with a high Akt activity.
Conclusions:: A decreased expression of PTEN may be an underlying mechanism for Akt activation. An Akt inhibitor may be a therapeutic option for a subset of RCC with an elevated Akt activity.
Key words: Akt, Bad, PTEN, renal cell carcinoma
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
One of the underlying mechanisms for an elevated Akt activation has been demonstrated to be an inactivation of the PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor gene, which is located on 10q23.3. PTEN is a lipid phosphatase which dephosphorylates the 3-position of phosphatidylinositol 3,4,5-triphosphate (PIP3) [7]. The binding of the pleckstrin homology domain (PH) of Akt to PIP3 on the inner leaflet of the plasma membrane releases the autoinhibitory function of the PH domain, thus allowing phosphoinositide-dependent kinase 1 (PDK1) to phosphorylate Akt. Therefore, PTEN antagonizes the PI3K activity by dephosphorylating PIP3 and thereby negatively regulating Akt.
Phosphorylated and activated Akt modulates the activity of a variety of downstream target proteins that are related to cell survival and proliferation. Proapoptotic protein Bad is known to be a major target protein of activated Akt. Akt phosphorylates and then inactivates Bad, thereby promoting cell survival [8]. Although mutations of the PTEN gene are infrequently observed in RCC [9
12
], a decreased PTEN protein expression has been frequently observed [13
]. These previous studies suggest that the loss of the PTEN function may be an underlying mechanism of Akt activation in RCC. However, the possible link between Akt activation and PTEN inactivation has not yet been documented in RCC.
In various malignant tumor cell lines, where increased Akt activities were observed, a disruption of Akt activation has been shown to inhibit cell proliferation and therefore has been considered to be a potentially novel therapeutic strategy [14]. Therefore, for RCC with an increased Akt activity, the inhibition of Akt activity can be a potential target for cancer intervention in RCC. However, such a therapeutic approach has never been previously attempted in RCC. At present, there is no effective treatment for advanced RCC with metastasis. Therefore, we attempted to perform a therapeutic approach using Akt inhibitor in RCC cell lines. We herein describe that Akt inhibitor-induced apoptosis in KU19-20 [15
] and Caki-2 cells. Constitutive Akt activation in these cell lines was attenuated by the Akt inhibitor in association with downstream Bad dephosphorylation and a reduced Bcl-xL expression.
![]() |
Materials and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Rabbit polyclonal antibodies against Akt, phospho-specific Akt at Ser473 (p-Akt), and Bcl-xL were obtained from the Transduction Laboratories (San Diego, CA). Rabbit polyclonal antibodies against Bad and the mouse monoclonal antibodies against PTEN were from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit polyclonal antibodies against Phospho-Bad at Ser136 (p-Bad) were obtained from Cell Signaling Technology, Inc. (Beverly, MA). A mouse monoclonal antibody against ß-actin came from Sigma (St Louis, MO).
Preparation of tissue extracts
Primary renal cancer tissue specimens were surgically resected from 45 patients with RCC at Keio University Hospital. Forty cases were clear cell type, three were papillary and two were chromophobe cell type. For the evaluation of Bad and phosphrylated Bad (p-Bad), 20 cases including 15 clear cell type, three papillary and two chromophobe were used. As for controls, normal renal tissue specimens were obtained from the surrounding tumor free tissues. These tissue specimens were stored at 80 °C until use. The tissue specimens were homogenized in 400 µl of ice-cold TNE buffer [20 mM TrisHCl (pH 7.4), 150 mM NaCl, 2 mM ethylenediaminetetraacetic acid (EDTA), 1% NP-40 (Roche Diagnostics, Mannheim, Germany), 50 mM NaF, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride (PMSF; Boehringer Mannheim, Mannheim, Germany), 10 µg/ml aprotinin and 10 µg/ml leupeptin (Roche Diagnostics)]. The homogenates were then centrifuged at 4 °C for 10 min at 12 000 g and then the protein concentrations in the supernatants were determined by the dye-binding method according to the manufacturer's instructions (Bio-Rad, Hercules, CA).
Western blotting
Supernatants of the homogenates from RCC, control renal tissues and cell lysates were electrophoresed by SDSPAGE (12% acrylamide) and transferred onto nitrocellulose membranes (Bio-Rad). Non-specific binding was blocked in Tris-buffered saline (TBS) containing 5% non-fat dry milk before incubation with primary antibodies. The concentration of the primary antibodies was 0.5 µg/ml for PTEN, Akt, p-Akt, Bcl-xL and ß-actin, 1.0 µg/ml for Bad and p-Bad. The primary antibodies were reacted overnight and second antibodies for 1 h. Immunoreactive bands were visualized by the amplified alkaline phosphatase system according to the manufacturer's instructions (Bio-Rad). The bands were scanned and quantitatively analyzed using the NIH Image 1.62 program (NIH, Bethesda, MD). The normalization of western blot analyses was performed using ß-actin. Namely, the ratio of Akt, p-Akt and PTEN to ß-actin was calculated. An analysis for ß-actin was done using another membrane. The same lysates used for PTEN, Akt, p-Akt, Bcl-xL, Bad and p-Bad were loaded onto another gel for ß-actin as an internal control.
Cell lines and cultures
Four different renal cancer cell lines, Caki-1, KU19-20, SW-839 and Caki-2 were cultured in an RPMI 1640 medium with 10% fetal bovine serum and streptomycin (100 µg/ml). KU19-20 is a renal cancer cell line established at our institute [15]. Caki-1, SW-839 and Caki-2 were purchased from the American Tissue Culture Collection (Rockville, MD). Prior to treatment with chemicals, they were serum-starved overnight. Caki-1 was derived from skin metastases of clear cell RCC. KU19-20 was obtained from subcutaneous metastases of clear cell RCC. SW-839 was from clear cell RCC. Caki-2 was from a primary lesion of clear cell RCC.
Cell viability assay
For testing the sensitivity to Akt inhibitor, 200 µl aliquots of cell suspension (5 x 104 cells/ml) were seeded in flat-bottom 96-well plates. After 24 h, the medium was replaced with a serum-free medium containing the indicated reagents and then was incubated for 24, 48 and 72 h. Cell viability was determined by an Alamar Blue assay (Iwaki Glass, Chiba, Japan). Fluorescence of the reduced Alamar Blue was measured on a fluoroscan (Titrek Fluoroskan II; Labsystems, Tokyo, Japan) at 590 nm by excitation at 544 nm. Each experiment was performed in triplicate.
Detection of apoptosis using the flow cytometric TUNEL method
After treatment with the Akt inhibitor (20 µM) for 48 h, adherent and non-adherent cells were pooled and fixed in 1% paraformaldehyde, permeablized in 70% ethanol and stored at 20 °C. Breaks at 3'-OH DNA were detected by the TUNEL technique using the Apotag Plus Fluorescein (FITC) kit (Oncor, Gaithersburg, MD) according to the supplier's instructions. FITC-labeled cells were stained with propidium iodide (PI) and analyzed by flow cytometry using an EPICS ALTRA flow cytometer (Beckman Coulter, Fullerton, CA).
Statistical analysis
The unpaired-t test was used to determine the differences of Akt, p-Akt and PTEN expression between RCC and corresponding normal kidney tissue. The growth inhibitory effect was evaluated by two-way ANOVA. A Spearman's rank correlation test was performed to examine the relationship.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
Induction of apoptosis by an Akt inhibitor in RCC cell lines
Akt activation is considered to be a frequent event in RCC [6]. We next developed a therapeutic approach targeting Akt activation in RCC cell lines. An Akt inhibitor, a phosphatidylinositol ether analog, was used to block the Akt activation. KU19-20 and Caki-2 have an activated Akt status whereas Caki-1 and SW839 have relatively low Akt activity. Inversely, KU19-20 and Caki-2 have a low PTEN expression, whereas Caki-1 and SW839 have a relatively high PTEN expression. Akt inhibitor decreased the cell viability in a dose-dependent manner (Figure 2A). The effect was prominent in KU19-20, moderate in Caki-2, whereas the effect was minimal in Caki-1 and SW839. The Akt inhibitor (20 µM, 48 h treatment) induced apoptosis in KU19-20 and Caki-2 cells as determined by a flowcytometric TUNEL assay (Figure 2B).
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In various types of human malignant tumors, an elevated Akt activation has been demonstrated and the mechanisms for Akt activation have been shown to depend on the types of tumors. For example, ovarian carcinomas and endometrial carcinoma have shown an increased Akt activation due to a high frequency of PTEN inactivation [3, 4
]. On the other hand, thyroid cancer, in which PTEN inactivation is uncommon, has shown an elevated Akt activation due to an overexpression of Akt [5
]. Recent studies have demonstrated that a somatic PTEN mutation in primary RCC and renal cancer cell lines is found at a relatively lower incidence than in other malignant tumors, such as glioblastoma, melanoma, prostate cancer and endometrial carcinoma [17
]. A PTEN mutation in RCC was thus found especially in high grade and advanced clear cell type RCC with distant metastases or renal vein tumor invasions, thus suggesting that PTEN mutations occur as a late-stage event and may contribute to an invasive and metastatic tumor phenotype [12
]. On the other hand, Brenner et al. [13
] demonstrated that a markedly reduced expression of PTEN was found in clear cell type RCC regardless of pathological grade and thus concluded that the PTEN expression was lost during early renal carcinogenesis. The discrepancy between the frequency of PTEN mutation and that of PTEN expression loss may be due to additional mechanisms for PTEN inactivation other than gene deletion and mutations, including promoter methylation or translational modification. Our results have shown that a decreased PTEN expression may predispose a constitutive Akt activation in RCC. Notably, these alterations, including Akt activation, decreased PTEN expression and Bad phosphorylation, were specifically observed in clear cell type, but not in papillary or chromophobe type RCC.
The Akt inhibitor induced apoptosis in KU19-20 and Caki-2 cells with a high Akt activity, whereas the Akt inhibitor had a minimal effect on the proliferation of Caki-1 and SW839 cells with a lower Akt activity. The Akt activity in KU19-20 and Caki-2 thus appears to be closely related to cancer cell survival, whereas in Caki-1 and SW839 cells with a low Akt activity, this signal pathway does not seem to play any role in cancer cell survival. These results suggest that the pre-treatment status of Akt activity may play a decisive role in the effectiveness of Akt inhibitor.
RCC, found asymptomatically in the early stages, can be treated by surgery with a favorable prognosis. Advanced RCC with metastasis has a poor prognosis because RCC is resistant to chemotherapy and radiotherapy, while immunotherapy, such as interferon and interleukin-2, the current treatment option, has only between a 15 and 20% efficacy [18]. As a result, a novel therapy for these patients is currently needed. To assess the functional relevance of Akt activation in cell survival, we used an Akt inhibitor and evaluated the inhibition of cell proliferation in parallel with the downregulation of Akt phosphorylation. In a subset of RCC with elevated Akt activation, Akt inhibitor therefore has a therapeutic potential for patients in whom there is no efficient therapy at present.
Interestingly, a prominent phosphorylation of Bad was observed in KU19-20 and Caki-2 cells, thus suggesting that proapoptotic Bad protein was inactivated. It is conceivable that phosphorylated Bad may play a role in the survival of KU19-20 and Caki-2 cells and that dephosphorylation by Akt inhibitor induces the cancer cells to undergo apoptosis. Bad phosphorylation may be closely related to aberrant survival, namely, carcinogenesis of RCC. In contrast, a proliferation of Caki-1 and SW839 cells had minimal effect by the Akt inhibitor. Notably, Caki-1 and SW839 cells had only a slight degree of Bad phosphorylation, therefore, Bad phosphorylation does not seem to contribute to the carcinogenesis of Caki-1 and SW839 cells. Targeting Akt signal cascades may have a therapeutic potential for clear cell type RCC with an elevated Akt activity.
![]() |
Acknowledgements |
---|
Received for publication August 5, 2004. Accepted for publication January 16, 2005.
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
2. Itoh N, Semba S, Ito M et al. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 2002; 94: 31273134.[CrossRef][ISI][Medline]
3. Kurose K, Zhou XP, Araki T et al. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 2001; 158: 20972106.
4. Kanamori Y, Kigawa J, Itamochi H et al. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res 2001; 7: 892895.
5. Ringel MD, Hayre N, Saito J et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 2001; 61: 61056111.
6. Horiguchi A, Oya M, Uchida A et al. Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. J Urol 2003; 169: 710713.[CrossRef][ISI][Medline]
7. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998; 273: 1337513378.
8. Datta SR, Dudek H, Tao X et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231241.[CrossRef][ISI][Medline]
9. Sakurada A, Suzuki A, Sato M et al. Infrequent genetic alterations of the PTEN/MMAC1 gene in Japanese patients with primary cancers of the breast, lung, pancreas, kidney, and ovary. Jpn J Cancer Res 1997; 88: 10251028.[ISI][Medline]
10. Cairns P, Evron E, Okami K et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 1998; 16: 32153218.[CrossRef][ISI][Medline]
11. Alimov A, Li C, Gizatullin R et al. Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma. Anticancer Res 1999; 19: 38413846.[ISI][Medline]
12. Kondo K, Yao M, Kobayashi K et al. PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines. Int J Cancer 2001; 91: 219224.[CrossRef][ISI][Medline]
13. Brenner W, Farber G, Herget T et al. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer 2002; 99: 5357.[CrossRef][ISI][Medline]
14. Yuan ZQ, Sun M, Feldman RI et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000; 19: 23242330.[CrossRef][ISI][Medline]
15. Tachibana M, Miyakawa A, Nakashima J et al. Autocrine growth promotion by multiple hematopoietic growth factors in the established renal cell carcinoma line KU-1920. Cell Tissue Res 2000; 301: 353367.[CrossRef][ISI][Medline]
16. Hu Y, Qiao L, Wang S et al. 3-(Hydroxymethyl)-be earing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. J Med Chem 2000; 43: 30453051.[CrossRef][ISI][Medline]
17. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489501.[CrossRef][ISI][Medline]
18. Figlin RA. Renal cell carcinoma: management of advanced disease. J Urol 1999; 161: 381386.[ISI][Medline]
|